Doctor watching herpatient sign paperwork

Phase I Unit

An integrated, scientifically driven approach to early-phase clinical development

An integrated, scientifically driven approach to early-phase clinical development

Bridging Early-Phase Insight to Late-Phase Development

Accelerating Early phase development

In an era where rising costs of drug development compel biotechs to seek efficiencies in research projects, the design of early phase studies and their impact on predicting late-phase outcomes are more critical than ever. As you navigate the intricate landscape of Phase I trials, you deserve a partner that not only appreciates the nuances, but also possesses the expertise to propel your projects forward with confidence. 

Unlike traditional Phase I Units, Medpace CRO’s  extensive experience in conducting Phase II-III trials equip us with a holistic understanding of clinical development. Bridging the gap between early and late phase trials, the Medpace Phase I Unit was established in 2008, an expansion that allowed us to underscore the importance of early-phase study design in shaping late phase outcomes. 

An Integrated, Scientifically-Driven Approach to Early-Phase Research

Discover the Medpace Phase I Unit’s state of the art facilities and comprehensive support services for accelerating early phase clinical development. Partner with us to bridge early phase insight to late phase successes.  

Leverage Full-Service Solutions for Early-Phase Studies

The Phase I Unit draws on the extensive expertise of the Medpace CRO to provide a full range of early-phase clinical research services, including regulatory consulting for early-phase development protocol design and writing, development of innovative processes for complex studies, pharmacokinetic and translational medicine consulting, project management, data management, and biostatistics.    

Early-Phase Services & Study Designs:

  • First in Human (FIH) 
  • Single Ascending Dose (SAD) 
  • Multiple Ascending Dose (MAD) 
  • Drug-Drug Interaction  
  • Food Effect 
  • Bio-availability  
  • Bio-equivalence or Biosimilar  
  • Thorough QR/QTc 
  • Crossover  
  • PK/PD 
  • Dose Escalation 
  • Phase IIa or Proof of Concept 
  • Device and Diagnostics 
  • Adaptive Design 

The Medpace Phase I Unit Facility

Innovation Meets Patient Comfort and Research Efficiency

The Medpace Phase I Unit facility offers excellence in research capabilities and provides high-end amenities to study participants. With the ability to conduct clinical pharmacology studies in four independent patient units, the state-of-the-art facility was built to accommodate small and large-scale studies. Its features include a 60,000 square-foot in-patient and out-patient facility, 85 beds (semiprivate and dormitory-style modules), centralized laboratory processing, licensed Investigational Drug Services Pharmacy, centralized food service, 24/7 security, and certified advanced cardiac life support (ACLS) personnel on staff.   

State of the Art Equipment:

  • Mortara Surveyor Telemetry Central System with 32 telemetry channels    
  • Mortara 12-lead ECG machines 
  • Welch Allyn Spot Vital Sign machines 
  • Fully stocked emergency crash carts with Zoll M Series defibrillator and external pacing device
  • Master clocks with synchronized time    
  • Generator back-up for continual power supply   
  • Laboratory processing and storage area with refrigerated centrifuges and –20*C/-70*C freezers  
  • Continuous temperature and humidity monitoring of lab and pharmacy areas by REES environmental monitoring system 

Dedicated Pharmacy for Early Phase Studies

Our Investigational Drug Services Pharmacy exclusively supports our Phase I Unit with full licenses from the Ohio Board of Pharmacy and DEA for controlled substances (schedule II-V). Equipped with ISO class 5-compounding septic isolator and dedicated pharmacy balances, we uphold rigorous standards of quality and safety. Our facility includes monitored refrigeration managed by REES monitoring system.

Recruitment and Retention Strategies

Effective Recruitment and Retention of Normal, Healthy, and Specialty Patient Populations

The Phase I Unit has a dedicated staff for the recruitment and screening of study subjects. We continuously develop and nurture our database of active potential study subjects for various types of clinical trials, helping enroll trials quickly and efficiently. 

Harnessing Technology to Streamline Study Management

Leveraging technology is essential for optimizing study management processes and driving efficiency in early phase clinical research. At the Medpace Phase I Unit, Sponsors benefit from our proprietary software, ClinTrak EDC which sets new standards for efficiency, transparency, and compliance. 

blue background

Hear from our Sponsors


“Medpace was an excellent partner throughout our Phase I obesity study. Their team was highly collaborative and responsive, with strong attention to both study execution and the care of our participants. Their expertise in conducting early-phase obesity studies, combined with their commitment to communication and operational excellence, gave us confidence throughout the study.”


Thorsten Kirschberg, PhD
Executive VP of Research, Biomea Fusion, Inc.

Embedded Physician Leadership

Our embedded physician leadership provides Sponsors with strategic medical guidance and diverse therapeutic expertise throughout early phase development. From protocol design to study completion, our Phase I physicians collaborate with Medpace’s broader medical, regulatory, and operational teams to address complex study requirements and to support participant safety, informed decision-making, and efficient study execution. Explore our expert leaders who are shaping early phase research:

Shabaz Khan, MD

Senior Director, Medpace Phase I Unit

Shabaz Khan, MD, has a background in Emergency Medicine and more than 22 years of industry experience. Dr. Khan currently serves as Senior Director of the Medpace Clinical Pharmacology Unit (MCPU). Dr. Khan has extensive expertise in the conduct and oversight of Early Phase clinical trials (Phases 1& 2) , along with TQT , DDI and BA/ BE studies. In his role, he is responsible for MCPU operations across all aspects of study execution, including staffing, training, and regulatory inspections. Dr. Khan provides oversight for all studies conducted at the MCPU, from protocol finalization and study planning through enrollment, conduct,  and completion.

Leela Vrishabhendra, MD

Senior Medical Director, Medpace Phase I Unit

Leela Vrishabhendra, MD, is a licensed internal medicine physician, currently serving as one of three PIs at the MCPU. Dr. Vrishabhendra received her medical degree from JSS Medical College in Mysore, India. She completed her internal medicine residency from Good Samaritan Hospital in Cincinnati in 2001. Prior to joining Medpace in June of 2014, Dr. Vrishabhendra was a practicing primary care physician in a large multi-specialty group in Cincinnati for 12 years.

fabric light dots

Get paid to change the
pace of medicine